MCRB Seres Therapeutics, Inc. - Common Stock
$4.59
价格 · 八月 19, 2026
截至...的财报数据 八月 5, 2026
52周区间
$4–$30
1% of range
分析师评级
BUY
8 analysts
目标价
$17
+270% upside
P/E (TTM)
7.2
ROE
14.8%
净利润率
721.9%
MCRB 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$4.59
市值
$44M
P/E (TTM)
7.2
每股收益 (TTM)
$0.64
营收 (TTM)
$789.0K
股息收益率
—
ROE
14.8%
负债/权益
—
52周区间
$4 – $30
MCRB 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$789.0K
2016-12-31
→
2025-12-31
EPS
$0.64
2020-12-31
→
2025-12-31
自由现金流
$865.0K
2016-12-31
→
2025-12-31
利润率
721.9%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
MCRB
同行中位数
P/E (TTM)
7.2
0.8
P/S (TTM) (市销率 (TTM))
55.8
6.2
P/B (市净率)
1.0
3.0
Price / FCF (股价/自由现金流)
50.9
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
MCRB
同行中位数
Operating Margin (营业利润率)
-11910.1%
—
Net Profit Margin (净利润率)
721.9%
-1056.6%
ROA
4.1%
-118.6%
ROE
14.8%
-139.5%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
MCRB
同行中位数
Current Ratio (流动比率)
2.6
2.1
Quick Ratio (速动比率)
2.4
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
MCRB
同行中位数
Revenue CAGR 3Y (营收3年复合年增长率)
-52.0%
—
Revenue CAGR 5Y (营收5年复合年增长率)
-52.7%
—
Net Income YoY (净利润同比增长)
4088.2%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
MCRB
同行中位数
MCRB 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
8 位分析师
- 强烈买入 2 25.0%
- 买入 5 62.5%
- 持有 1 12.5%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
2 位分析师 · 2026-08-15
中位数
$17.00
← 低于所有目标
$4.59
最低
$12.00
最高
$22.00
中位数目标
$17.00
+270.4%
平均目标
$17.00
+270.4%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.26%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.50 | $-2.23 | 0.73% |
| 2026年3月31日 | $-2.08 | $-1.92 | -0.16% |
| 2025年12月31日 | $-1.78 | $-2.15 | 0.37% |
| 2025年9月30日 | $0.94 | $1.31 | -0.37% |
| 2025年6月30日 | $-2.27 | $-2.54 | 0.27% |
| 2025年3月31日 | $-2.96 | $-0.55 | -2.4% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| MCRB | $142M | 23.2 | — | 721.9% | 14.8% | — |
| MGX | $61M | -0.7 | -51.8% | -348.5% | -49.6% | — |
| KPTI | $135M | -0.4 | 0.57% | -134.2% | 73.7% | — |
| ALGS | $58M | -3.8 | -39.5% | -1106.7% | -31.1% | — |
| CRVO | $73M | — | -58.9% | -673.1% | -104.4% | — |
| TVGN | — | — | — | — | — | — |
| ELUT | — | 0.8 | -15.0% | 434.2% | -753.4% | 53.7% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789.0K | $0 | $0 | $7M | $145M | $33M | $35M | $28M | $32M | $22M | $0 | |
| R&D Expense | $49M | $65M | $118M | $110M | $142M | $91M | $80M | $96M | $89M | $82M | $38M | |
| SG&A Expense | $39M | $53M | $78M | $70M | $69M | $31M | $25M | $33M | $34M | $33M | $17M | |
| Operating Expenses | $95M | $121M | $195M | $180M | $209M | $121M | $106M | $129M | $123M | $115M | $55M | |
| Operating Income | $-94M | $-121M | $-195M | $-180M | $-64M | $-88M | $-72M | $-100M | $-91M | $-93M | $-55M | |
| Interest Income | $2M | $4M | $7M | $3M | $3M | $946.0K | $1M | $1M | $2M | · | · | |
| Other Non-op | $17M | $-14M | $134.0K | $-705.0K | $-1M | $981.0K | $1M | $1M | $2M | $1M | $76.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $6M | $136.0K | $-114M | $-250M | $-66M | $-89M | $-70M | $-99M | $-89M | $-92M | $-55M | |
| EPS (Basic) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | · | · | · | · | · | |
| EPS (Diluted) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | · | · | · | · | · | |
| Shares (Basic) | 8,858,975 | 7,769,910 | 6,400,339 | 108,077,043 | 91,702,866 | 79,789,220 | · | · | · | · | · | |
| Shares (Diluted) | 8,869,742 | 7,769,910 | 6,400,339 | 108,077,043 | 91,702,866 | 79,789,220 | · | · | · | · | · | |
| EBITDA | $-90M | $-116M | $-102M | $-240M | $-59M | $-82M | $-64M | $-92M | $-84M | $-89M | $-54M |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $31M | $128M | $163M | $180M | $116M | $65M | $86M | $36M | $55M | $74M | |
| Short-term Investments | · | · | $0 | $18M | $111M | $138M | $30M | · | $114M | $139M | $131M | |
| Receivables | $157.0K | $0 | · | · | · | $9M | $2M | · | · | · | · | |
| Inventory | · | · | $30M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $3M | $6M | $8M | $13M | $13M | $6M | $4M | $7M | $5M | $5M | $3M | |
| Current Assets | $49M | $39M | $175M | $195M | $304M | $269M | $100M | $93M | $155M | $198M | $208M | |
| PP&E (Net) | $8M | $12M | $18M | $23M | $18M | $14M | $19M | $26M | $33M | $36M | $8M | |
| PP&E (Gross) | $64M | $65M | $67M | $68M | $58M | $48M | $47M | $47M | $45M | $41M | $9M | |
| Accum. Depreciation | $57M | $53M | $49M | $45M | $40M | $34M | $28M | $20M | $12M | $5M | $1M | |
| Other Non-current Assets | $31.0K | $31.0K | $2M | $10M | $5M | · | · | · | · | · | · | |
| Total Assets | $138M | $140M | $359M | $349M | $355M | $343M | $132M | $120M | $190M | $273M | $217M | |
| Accounts Payable | $2M | $4M | $4M | $17M | $14M | $4M | $5M | $6M | $7M | $8M | $5M | |
| Short-term Debt | · | · | $0 | $456.0K | $0 | $454.0K | · | · | · | · | · | |
| Current Liabilities | $19M | $41M | $99M | $86M | $82M | $46M | $46M | $42M | $32M | $30M | $11M | |
| Capital Leases | $73M | $83M | $92M | $108M | $18M | $11M | $16M | · | · | · | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $1M | $11M | $1M | $502.0K | $644.0K | $1M | · | · | |
| Total Liabilities | $94M | $126M | $403M | $338M | $223M | $168M | $181M | $169M | $129M | $140M | $12M | |
| Long-term Debt | · | · | $110M | $50M | $24M | $25M | $25M | · | · | · | · | |
| Total Debt | · | · | $0 | $456.0K | · | $454.0K | · | · | · | · | · | |
| Common Stock | $10.0K | $9.0K | $135.0K | $125.0K | $92.0K | $91.0K | $70.0K | $41.0K | $40.0K | $40.0K | $39.0K | |
| Retained Earnings | $-972M | $-978M | $-978M | $-865M | $-614M | $-549M | $-460M | $-389M | $-264M | $-174M | $-83M | |
| AOCI | · | $0 | $0 | $-12.0K | $-60.0K | $-47.0K | · | · | $-146.0K | $-149.0K | $30.0K | |
| Stockholders' Equity | $44M | $14M | $-45M | $11M | $132M | $175M | $-48M | $-48M | $61M | $133M | $205M | |
| Liabilities + Equity | $138M | $140M | $359M | $349M | $355M | $343M | $132M | $120M | $190M | $273M | $217M | |
| Shares Outstanding | 9,556,466 | 8,650,227 | 6,752,073 | 6,261,400 | 91,889,418 | 91,459,239 | 70,143,252 | 40,936,735 | 40,571,015 | 40,355,753 | 39,082,017 |
现金流 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $5M | $6M | $7M | $6M | $7M | $8M | $8M | $7M | $4M | $728.0K | |
| Stock-based Comp | $11M | $21M | $34M | $25M | $20M | $9M | $8M | $17M | $17M | $17M | $10M | |
| Restructuring | $1M | · | $6M | · | $0 | $0 | $1M | $0 | $0 | · | · | |
| Other Non-cash | $-20M | $-175M | $-44M | $-11M | $46M | $-20M | $-22M | $12M | $-11M | $114M | $4M | |
| Operating Cash Flow | $1M | $-149M | $-117M | $-229M | $7M | $-94M | $-77M | $-63M | $-76M | $44M | $-41M | |
| CapEx | $252.0K | $380.0K | $8M | $10M | $10M | $591.0K | $1M | $2M | $5M | $21M | $4M | |
| Investing Cash Flow | $-42.0K | $142M | $11M | $82M | $64M | $-159M | $-31M | $112M | $56M | $-66M | · | |
| Debt Issued | · | · | · | $28M | $0 | $0 | $25M | · | · | · | · | |
| Net Debt Issued | · | · | · | $28M | · | · | $25M | · | · | · | · | |
| Stock Issued | · | $0 | $0 | $97M | $0 | $244M | $61M | · | · | · | $143M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | $33.0K | · | · | |
| Net Stock Activity | · | $0 | $0 | $97M | · | $244M | $61M | · | $-33.0K | · | $143M | |
| Financing Cash Flow | $14M | $-90M | $72M | $130M | $1M | $303M | $86M | $268.0K | $83.0K | $2M | · | |
| Net Change in Cash | · | · | · | · | · | $51M | $-21M | $50M | $-20M | $-20M | $-40M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $865.0K | $-149M | $-125M | $-239M | $-3M | $-94M | $-78M | $-65M | $-80M | $22M | $-45M |
盈利能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -11910.1% | · | -85.5% | -3458.1% | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% | · | |
| Net Margin | 721.9% | · | -90.0% | -3509.5% | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% | · | |
| EBITDA Margin | -11386.3% | · | -80.5% | -3365.1% | -40.4% | -245.5% | -186.3% | -327.0% | -262.1% | -407.2% | · | |
| ROA | 4.1% | 0.05% | -32.1% | -71.1% | -18.8% | -37.5% | -55.6% | -63.8% | -38.7% | -37.4% | -32.8% | |
| ROE | 14.8% | 0.72% | 379.2% | -638.4% | -42.7% | -49.1% | 174.5% | 251.7% | -92.5% | -54.2% | -61.3% |
流动性与偿付能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | 0.9 | 1.8 | 2.3 | 3.7 | 5.8 | 2.2 | 2.2 | 4.9 | 6.5 | 19.0 | |
| Quick Ratio | 2.4 | 0.7 | 1.3 | 2.1 | 3.5 | 5.7 | 1.5 | 2.0 | 4.7 | 6.3 | 18.8 | |
| Debt / Equity | · | · | 0.0 | 0.0 | · | 0.0 | · | · | · | · | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.4 | 0.0 | 0.4 | 0.1 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 | |
| Receivables Turnover | 10.1 | · | · | · | · | 5.9 | 38.7 | · | · | · | · |
增长率 4
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -95.1% | 336.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -52.0% | · | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -52.7% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 4088.2% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $789.0K | $0 | $0 | $7M | $145M | $33M | $35M | $28M | $32M | $22M | $0 | |
| Net Income TTM | $6M | $136.0K | $-114M | $-250M | $-66M | $-89M | $-70M | $-99M | $-89M | $-92M | $-55M | |
| Market Cap | $142M | $2.88B | $3.78B | $14.02B | $15.31B | $44.82B | $4.84B | $3.70B | $8.23B | $7.99B | $27.43B | |
| Enterprise Value | · | · | $3.65B | $13.84B | · | $44.56B | · | · | · | · | · | |
| P/E | 23.2 | · | -1.6 | -48.5 | -231.4 | -437.5 | · | · | · | · | · | |
| P/S | 180.2 | · | · | 1967.6 | 105.6 | 1349.2 | 140.3 | 130.9 | 256.3 | 367.1 | · | |
| P/B | 3.2 | 208.6 | -84.3 | 1300.6 | 116.4 | 256.5 | -100.2 | -77.0 | 135.6 | 60.2 | 133.5 | |
| P / Tangible Book | 3.2 | 208.6 | · | 1300.6 | 116.4 | 256.5 | · | · | · | · | · | |
| P / Cash Flow | 127.3 | -19.3 | -32.2 | -61.3 | 2289.0 | -478.7 | -63.2 | -58.9 | -108.9 | 181.9 | -671.5 | |
| P / FCF | 164.4 | -19.3 | -30.2 | -58.8 | -5319.2 | -475.7 | -62.4 | -57.1 | -102.6 | 356.3 | -606.7 | |
| EV / EBITDA | · | · | -35.9 | -57.7 | · | -546.4 | · | · | · | · | · | |
| EV / FCF | · | · | -29.1 | -58.0 | · | -473.1 | · | · | · | · | · | |
| EV / Revenue | · | · | · | 1942.2 | · | 1341.6 | · | · | · | · | · | |
| Earnings Yield | 4.3% | 0.00% | -63.5% | -2.1% | -0.43% | -0.23% | · | · | · | · | · |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $736.0K | $358.0K | $438.0K | $351.0K | $0 | $0 | $0 | $0 | $0 | $0 | $-126M | $310.0K | $126M | $-522.0K | · | $3M | |
| R&D Expense | $9M | $13M | $12M | $13M | $13M | $12M | $13M | $16M | $16M | $19M | $2M | $25M | $47M | $44M | $-17M | $43M | |
| SG&A Expense | $7M | $8M | $8M | $9M | $10M | $12M | $12M | $13M | $13M | $15M | $8M | $19M | $28M | $22M | $13M | $18M | |
| Operating Expenses | $22M | $21M | $20M | $23M | $25M | $27M | $29M | $29M | $29M | $34M | $4M | $45M | $77M | $70M | $-4M | $63M | |
| Operating Income | $-21M | $-21M | $-19M | $-22M | $-25M | $-27M | $-29M | $-29M | $-29M | $-34M | $-129M | $-45M | $50M | $-71M | $-2M | $-59M | |
| Interest Income | $181.0K | $325.0K | $445.0K | $618.0K | $546.0K | $618.0K | $437.0K | $652.0K | $1M | $2M | $2M | $3M | $2M | $1M | $1M | $865.0K | |
| Other Non-op | $673.0K | $669.0K | $2M | $3M | $4M | $7M | $6M | $-23M | $1M | $505.0K | $336.0K | $999.0K | $-2M | $310.0K | $-23.0K | $-33.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $5M | $-20M | $-15M | $8M | $-20M | $33M | $-16M | $89M | $-33M | $-40M | $-41M | $-48M | $47M | $-71M | $-69M | $-60M | |
| EPS (Basic) | $0.47 | $-2.08 | $-1.79 | $0.94 | $-2.27 | $3.76 | $-1.80 | $11.63 | $-4.34 | $-5.49 | $-17.19 | $-0.37 | $0.36 | $-0.57 | $-0.51 | $-0.49 | |
| EPS (Diluted) | $0.47 | $-2.08 | $-1.78 | $0.94 | $-2.27 | $3.75 | $-1.80 | $11.63 | $-4.34 | $-5.49 | $-17.19 | $-0.37 | $0.36 | $-0.57 | $-0.51 | $-0.49 | |
| Shares (Basic) | 9,706,193 | 9,582,533 | -17,346,671 | 8,758,692 | 8,743,733 | 8,703,221 | -14,742,978 | 7,632,242 | 7,575,620 | 7,305,026 | -375,465,993 | 128,289,871 | 127,713,486 | 125,862,975 | -198,870,067 | 122,527,275 | |
| Shares (Diluted) | 9,747,138 | 9,582,533 | -17,360,211 | 8,771,519 | 8,743,733 | 8,714,701 | -14,742,978 | 7,632,242 | 7,575,620 | 7,305,026 | -377,597,438 | 128,289,871 | 129,844,931 | 125,862,975 | -198,870,067 | 122,527,275 | |
| EBITDA | $-21M | $-20M | · | $-21M | $-24M | $-26M | · | $-28M | $-30M | $-38M | · | $-46M | $51M | $-69M | · | $-57M |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $30M | $46M | $48M | $45M | $59M | $31M | $67M | $71M | $111M | · | $170M | $230M | $95M | · | $205M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $12M | · | $28M | |
| Receivables | $274.0K | $233.0K | $157.0K | $351.0K | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | · | · | · | · | · | · | · | · | $53M | $42M | · | $19M | $5M | · | · | · | |
| Prepaid Expense | $1M | $2M | $3M | $3M | $2M | $4M | $6M | $6M | $6M | $5M | · | $9M | $9M | $10M | · | $15M | |
| Current Assets | $42M | $32M | $49M | $52M | $49M | $66M | $39M | $73M | $149M | $165M | · | $214M | $251M | $116M | · | $248M | |
| PP&E (Net) | $6M | $7M | $8M | $9M | $10M | $11M | $12M | $13M | $18M | $19M | · | $24M | $24M | $24M | · | $19M | |
| PP&E (Gross) | $61M | $64M | $64M | $65M | $65M | $65M | $65M | $65M | $72M | $72M | · | $73M | $72M | $71M | · | $65M | |
| Accum. Depreciation | $55M | $57M | $57M | $56M | $55M | $54M | $53M | $52M | $54M | $52M | · | $50M | $48M | $46M | · | $45M | |
| Other Non-current Assets | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $31.0K | $465.0K | $42M | $41M | · | $12M | $11M | $11M | · | $12M | |
| Total Assets | $102M | $118M | $138M | $143M | $144M | $164M | $140M | $179M | $322M | $341M | · | $368M | $406M | $270M | · | $312M | |
| Accounts Payable | $1M | $2M | $2M | $2M | $2M | $2M | $4M | $8M | $5M | $5M | · | $9M | $13M | $12M | · | $10M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | · | · | |
| Current Liabilities | $20M | $19M | $19M | $22M | $31M | $31M | $41M | $65M | $108M | $98M | · | $79M | $78M | $64M | · | $82M | |
| Capital Leases | $45M | $70M | $73M | $75M | $78M | $80M | $83M | $85M | $101M | $103M | · | $105M | $107M | $107M | · | $18M | |
| Other Non-current Liabilities | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $1M | · | $961.0K | |
| Total Liabilities | $67M | $91M | $94M | $100M | $111M | $114M | $126M | $155M | $409M | $401M | · | $383M | $384M | $318M | · | $244M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $110M | $110M | · | $110M | $110M | $50M | · | $50M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | · | · | |
| Common Stock | $10.0K | $10.0K | $10.0K | $9.0K | $9.0K | $9.0K | $9.0K | $170.0K | $152.0K | $151.0K | · | $129.0K | $128.0K | $127.0K | · | $124.0K | |
| Retained Earnings | $-988M | $-992M | $-972M | $-957M | $-965M | $-945M | $-978M | $-962M | $-1.05B | $-1.02B | · | $-937M | $-889M | $-936M | · | $-796M | |
| AOCI | · | · | · | $0 | $0 | · | · | $0 | $0 | $0 | · | $0 | $-1.0K | $2.0K | · | $-118.0K | |
| Stockholders' Equity | $35M | $26M | $44M | $44M | $33M | $50M | $14M | $24M | $-87M | $-60M | $-45M | $-15M | $23M | $-48M | $11M | $68M | |
| Liabilities + Equity | $102M | $118M | $138M | $143M | $144M | $164M | $140M | $179M | $322M | $341M | · | $368M | $406M | $270M | · | $312M | |
| Shares Outstanding | 9,827,569 | 9,592,326 | 9,556,446 | 8,764,664 | 8,754,482 | 8,732,187 | 8,650,227 | 170,200,253 | 151,633,922 | 151,442,034 | 6,752,073 | 128,630,689 | 128,037,679 | 126,592,604 | 125,222,273 | 124,410,917 |
现金流 11
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $670.0K | $781.0K | $954.0K | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | |
| Stock-based Comp | $2M | $2M | $3M | $2M | $2M | $3M | $4M | $5M | $6M | $6M | $5M | $9M | $13M | $7M | $7M | $6M | |
| Restructuring | $0 | $914.0K | $0 | $1M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $1M | · | · | · | $-10M | · | · | · | $-3M | · | · | · | $-14M | · | · | |
| Operating Cash Flow | $-22M | $-16M | $-15M | $2M | $-13M | $27M | $-39M | $-35M | $-40M | $-35M | $-47M | $-59M | $66M | $-77M | $-53M | $-60M | |
| CapEx | $0 | $0 | $29.0K | $8.0K | $181.0K | $34.0K | $90.0K | $129.0K | $99.0K | $62.0K | $877.0K | $2M | $1M | $4M | $3M | $1M | |
| Investing Cash Flow | $14.0K | $0 | $181.0K | $-8.0K | $-181.0K | $-34.0K | $-90.0K | $141M | $1M | $-62.0K | $-877.0K | $-2M | $11M | $3M | $6M | $40M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-3M | · | |
| Financing Cash Flow | $2M | $428.0K | $13M | $61.0K | $0 | $1M | $2M | $-111M | $0 | $19M | $6M | $1M | $58M | $6M | $5M | $98M | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | · | $135M | $-68M | · | $79M | |
| Free Cash Flow | · | $-16M | · | · | · | $27M | · | · | · | $-35M | · | · | · | $-81M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2890.3% | -5839.9% | · | -6403.7% | · | · | · | · | · | · | · | -15294.5% | 39.2% | 13518.8% | · | -1716.2% | |
| Net Margin | 622.4% | -5562.3% | · | 2337.3% | · | · | · | · | · | · | · | -15436.8% | 36.8% | 13634.9% | · | -1742.2% | |
| EBITDA Margin | -2799.3% | -5621.8% | · | -6106.3% | · | · | · | · | · | · | · | -14751.3% | 40.4% | 13250.6% | · | -1665.5% | |
| ROA | 3.7% | -14.1% | · | 5.1% | -8.5% | 12.9% | · | 32.5% | -9.0% | -13.1% | · | -14.1% | 13.7% | -24.1% | · | -17.0% | |
| ROE | 13.6% | -51.7% | · | 24.3% | 73.4% | -704.9% | · | 2018.6% | 102.0% | 74.6% | · | -182.4% | 203.8% | -430.2% | · | -49.3% |
流动性与偿付能力 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 1.6 | · | 2.3 | 1.6 | 2.1 | · | 1.1 | 1.4 | 1.7 | · | 2.7 | 3.2 | 1.8 | · | 3.0 | |
| Quick Ratio | 0.8 | 1.6 | · | 2.1 | 1.5 | 1.9 | · | 1.0 | 0.7 | 1.1 | · | 2.1 | 2.9 | 1.7 | · | 2.8 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | · |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.4 | -0.0 | · | 0.0 | |
| Receivables Turnover | 1.0 | 0.3 | · | 0.4 | · | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | · | · | · | $310.0K | $310.0K | · | $310.0K | $127M | $126M | · | $130M | $131M | $6M | · | $133M | |
| Net Income TTM | $-27M | $1M | · | $110M | $69M | $48M | · | $-32M | $-74M | $-113M | · | $-132M | $-149M | $-253M | · | $-113M | |
| Market Cap | $78M | $85M | · | $169M | $97M | $122M | · | $3.22B | $2.20B | $2.34B | · | $6.12B | $12.27B | $14.36B | · | $15.97B | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | $5.95B | $12.04B | $14.25B | · | · | |
| P/E | -2.7 | 26.1 | · | 1.4 | 1.3 | 2.5 | · | 13.2 | -1.5 | -2.6 | · | -44.5 | -68.4 | -47.8 | · | -118.9 | |
| P/S | 53.7 | · | · | · | 313.7 | 394.4 | · | 10387.7 | 17.3 | 18.6 | · | 47.2 | 93.9 | 2549.4 | · | 120.2 | |
| P/B | 2.2 | 3.2 | · | 3.9 | 3.0 | 2.4 | · | 134.6 | -25.2 | -39.2 | · | -404.9 | 542.4 | -299.9 | · | 236.4 | |
| P / Tangible Book | 2.2 | 3.2 | · | 3.9 | 3.0 | 2.4 | · | 134.6 | · | · | · | · | 542.4 | · | · | 236.4 | |
| P / Cash Flow | · | -5.2 | · | · | · | 4.5 | · | · | · | -66.5 | · | · | · | -187.4 | · | · | |
| P / FCF | · | -5.2 | · | · | · | 4.5 | · | · | · | -66.4 | · | · | · | -178.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | -130.2 | 235.8 | -206.0 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -176.7 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | 45.9 | 92.2 | 2530.5 | · | · | |
| Earnings Yield | -37.3% | 3.8% | · | 73.0% | 78.9% | 39.6% | · | 7.6% | -68.0% | -39.2% | · | -2.2% | -1.5% | -2.1% | · | -0.84% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $789.0K | $0 | $0 | $7M | $145M |
| 营业利润率 % | -11910.1% | — | -85.5% | -3458.1% | -44.5% |
| 净收入 | $6M | $136.0K | $-114M | $-250M | $-66M |
| 稀释后每股收益 (EPS) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | — | — | 0.0 | 0.0 | — |
| 流动比率 | 2.6 | 0.9 | 1.8 | 2.3 | 3.7 |
| 速动比率 | 2.4 | 0.7 | 1.3 | 2.1 | 3.5 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $865.0K | $-149M | $-125M | $-239M | $-3M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 43 家申报者 · $15.5M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 13 (+7 与上一季度对比) | 5 (-2 与上一季度对比) | 6 (-3 与上一季度对比) | 12 (+1 与上一季度对比) | -96K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 32 位内幕人士 · 16 位高管 · 17 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Richard N Kender | Interim Chief Executive Officer | 2026年7月8日 A | 63492 | 0 | 0 | $0 |
| Marella Thorell | EVP and Chief Financial Officer | 2026年7月8日 A | — | 0 | 0 | $0 |
| David Arkowitz | Chief Financial Officer | 2024年2月15日 M | 182442 | 0 | 0 | $0 |
| Matthew R. Henn | President and Chief Scientific Officer | 2026年8月15日 M | 7995 | 0 | 5 | $-24664 |
| Kelly Brady | EVP, Chief Operating Officer | 2026年8月15日 M | 8679 | 0 | 2 | $-735 |
| Thomas Desrosier | EVP and Chief Legal Officer | 2026年8月15日 M | 8117 | 0 | 5 | $-4209 |
| Teresa L. Young | EVP, Chief Commercial & Strategy Officer | 2026年2月15日 M | 8557 | 0 | 3 | $-19644 |
| Lisa Von Moltke | Executive Vice President and Chief Medical Officer | 2025年2月15日 M | 39875 | 0 | 0 | $0 |
| David S. Ege | Executive Vice President and Chief Technology Officer | 2024年8月15日 M | 77575 | 0 | 0 | $0 |
| Paula Cloghessy | Executive Vice President, Chief People Officer | 2023年10月27日 M | 45684 | 0 | 0 | $0 |
| Marcus Chapman | SVP, Principal Financial and Accounting Officer | 2021年2月4日 A | 8600 | 0 | 0 | $0 |
| John G. Aunins | Chief Technology Officer & EVP | 2020年1月29日 A | 105250 | 0 | 0 | $0 |
| David N Cook | Chief Scientific Officer and EVP of R&D | 2019年1月26日 M | 147435 | 0 | 0 | $0 |
| Kevin Horgan | Chief Medical Officer and EVP | 2019年1月25日 A | — | 0 | 0 | $0 |
| Michele Trucksis | Chief Medical Officer and EVP | 2018年1月30日 A | 4893 | 0 | 0 | $0 |
| Wael Hashad | EVP & Chief Commercial Officer | 2017年1月26日 A | — | 0 | 0 | $0 |
| Eric D. Shaff | 董事 | 2026年8月15日 M | 12499 | 0 | 5 | $-12708 |
| Stephen Berenson | 董事 | 2026年7月8日 A | 3589 | 0 | 0 | $0 |
| Robert L. Rosiello | 董事 | 2026年7月8日 A | — | 0 | 0 | $0 |
| Kurt Graves | 董事 | 2026年7月8日 A | — | 0 | 0 | $0 |
| Claire Fraser | 董事 | 2026年7月8日 A | — | 0 | 0 | $0 |
| Dennis A Ausiello | 董事 | 2026年7月8日 A | — | 0 | 0 | $0 |
| Willard H Dere | 董事 | 2026年7月8日 A | 31746 | 0 | 0 | $0 |
| Paul Biondi | 董事 | 2025年4月10日 A | 47619 | 0 | 0 | $0 |
| Hans-Juergen Woerle | 董事 | 2025年2月4日 A | — | 0 | 0 | $0 |
| Gregory Behar | 董事 | 2023年6月22日 A | — | 0 | 0 | $0 |
| Meryl Zausner | 董事 | 2022年7月5日 A | 31746 | 0 | 0 | $0 |
| AFEYAN NOUBAR | 董事 | 2019年6月18日 P | 4444444 | 0 | 0 | $0 |
| Lorence H. Kim | 董事 | 2019年6月13日 A | — | 0 | 0 | $0 |
| Roger Pomerantz | 董事 | 2019年6月13日 A | 213976 | 0 | 0 | $0 |
| Peter Barton Hutt | 董事 | 2016年6月15日 A | — | 0 | 0 | $0 |
| Werner Cautreels | 董事 | 2015年6月25日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 4 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Nestlé S.A., Société des Produits Nestlé S.A. | 2024年10月2日 | — | 初始申报 | — | SEC |
| Nestle Health Science US Holdings, Inc., NIMCO US, Inc., Nestlé S.A., Nestlé US Holdco, Inc., Société des Produits Nestlé S.A. ×2 申报 | 2022年7月22日 | — | 初始申报 | — | SEC |
| Flagship VentureLabs IV, LLC (2), Flagship Ventures Fund IV, L.P. (2), Flagship Ventures Fund IV-Rx, L.P. (2), Flagship Ventures Fund IV General Partner LLC (2), Nutritional Health LTP Fund, L.P. (2), Nutritional Health LTP Fund General Partner LLC (2), Flagship Pioneering Fund VI, L.P. (2), Flagship Pioneering Fund VI General Partner LLC (2), Flagship Pioneering Fund VII, L.P. (2), Flagship Pioneering Fund VII General Partner LLC (2), Flagship Pioneering, Inc. (2), Noubar B. Afeyan, Ph.D. (2) ×3 申报 | 2022年7月7日 | — | 初始申报 | — | SEC |
| Nestle Health Science US Holdings, Inc. (1), NIMCO US, Inc. (1), Nestlé S.A., Nestlé US Holdco, Inc. (1), Société des Produits Nestlé S.A. | 2020年8月19日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 8 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| AVSC · AMERICAN CENTURY ETF TRUST | 0.00% | 5277 NS | 2026年5月31日 | N-PORT |
| AVUV · AMERICAN CENTURY ETF TRUST | 0.00% | 37364 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.00% | 31077 NS | 2026年5月31日 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.00% | 1022 NS | 2026年5月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| IWC · iShares Trust | — | — | 2026年8月18日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年7月13日 | 每日 |